Dianthus Therapeutics gains 7.1% holder T. Rowe Price
DIANTHUS THERAPEUTICS INC reported that T. Rowe Price Investment Management, Inc. holds a significant position in its common stock.
Rhea-AI Filing Summary
DIANTHUS THERAPEUTICS INC reported that T. Rowe Price Investment Management, Inc. holds a significant position in its common stock. T. Rowe Price Investment Management is shown as beneficially owning 3,888,456 shares of common stock, representing 7.1% of the outstanding class.
The firm reports sole voting power over 3,884,903 shares and sole dispositive power over 3,888,456 shares, with no shared voting or dispositive power. T. Rowe Price Investment Management states that this filing should not be construed as an admission that it is the beneficial owner of these securities, and such beneficial ownership is expressly denied.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
beneficially owned financial
sole voting power financial
sole dispositive power financial
percent of class financial
CUSIP Number financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake in DIANTHUS THERAPEUTICS INC (DNTH) does T. Rowe Price Investment Management report?
How much voting power does T. Rowe Price Investment Management have in DNTH?
What percentage of DIANTHUS THERAPEUTICS (DNTH) common stock is reported as owned?
AI-generated analysis. How Rhea-AI works. Not financial advice.